Cargando…
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows
Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease affecting 0.5–1% of the population worldwide. Interstitial lung disease (ILD) is a serious pulmonary complication of RA and it is responsible for 10–20% of mortality, with a mean survival of 5–8 years. However, nowadays there a...
Autores principales: | Cassone, Giulia, Manfredi, Andreina, Vacchi, Caterina, Luppi, Fabrizio, Coppi, Francesca, Salvarani, Carlo, Sebastiani, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230307/ https://www.ncbi.nlm.nih.gov/pubmed/32290218 http://dx.doi.org/10.3390/jcm9041082 |
Ejemplares similares
-
Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease
por: Vacchi, Caterina, et al.
Publicado: (2020) -
Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
por: Cassone, Giulia, et al.
Publicado: (2020) -
Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis
por: Vacchi, Caterina, et al.
Publicado: (2021) -
Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease
por: Vacchi, Caterina, et al.
Publicado: (2021) -
Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review
por: Cassone, Giulia, et al.
Publicado: (2021)